Authors

Latest:

Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC

Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.

Ryan Sullivan, MD

Latest:

Future Directions in Metastatic Uveal Melanoma Treatment

Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.

Ryan W. Huey, MD

Latest:

Dr. Huey on Challenges Faced With Immunotherapy in HCC

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

Ryan W. Jacobs, MD

Latest:

Expert Insights into Investigation Therapies for CLL

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

S. Gail Eckhardt, MD

Latest:

Dr. Eckhardt on the Wnt Pathway in Colorectal Cancer

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

S. Lindsey Davis, MD

Latest:

Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ Cancer

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.

S. Vincent Rajkumar, MD

Latest:

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

S. Yousuf Zafar, MD

Latest:

Dr. Zafar on the Potential of Immunotherapy in Colorectal Cancer

S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Saad Usmani, MD, Levine Cancer Institute

Saad Z. Usmani, MD

Latest:

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

Saad Z. Usmani, MD, FACP

Latest:

Dr Usmani on Approaching Treatment Decisions in High-Risk Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.

Saad Z. Usmani, MD, FACP, Levine Cancer Institute

Latest:

“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting

Saad Z. Usmani, MD, Levine Cancer Institute/Carolinas Healthcare System

Saby George, MD, FACP, Roswell Park

Latest:

The Next Chapter in RCC Recontextualizes Treatment Considerations

Renal cell carcinoma is one of the top 10 most common cancers, although incidence rates have been stable over the past decade. It is more common in men than women and rates are higher among African American, American Indian, and Alaska Native patient populations.

Sachin H. Jain, MD, MBA

Latest:

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.

Saeed Rafii, MD, PhD

Latest:

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Safi Shahda, MD

Latest:

Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

Sagar B. Kudchodkar, PhD

Latest:

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

Sagar Lonial, MD

Latest:

Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Sagar Lonial, MD, Emory